In conclusion, the findings presented herein suggest that MT1‐MMP constitutes an attractive target by which to halt the progression of joint damage in RA and to improve treatment outcomes in these patients, especially in those with an inadequate response to anti‐TNF therapy. This evidence concerns the gene TNF and rheumatoid arthritis.